ArticleFrontiers in immunology2026
Point-of-care assessment of complement activation in the ICU: a feasibility study of rapid terminal complement complex detection in critical illness.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Complement activation is increasingly recognized as a key driver in various critical diseases and a potential therapeutic target. However, conventional enzyme-linked immunosorbent assays (ELISAs) for complement protein detection are laboratory-bound and unsuitable for rapid clinical decision-making in the emergency and intensive care unit setting. We evaluated the feasibility of a point-of-care (POC) multiplex micro-ELISA for complement component C3, activation marker C3d and the soluble terminal complement complex (TCC) in a heterogeneous intensive care unit (ICU) population. Method: Thirty-eight critically ill and three cardiopulmonary bypass patients were prospectively enrolled. Fifteen age- and sex-matched healthy volunteers served as controls. Plasma samples collected at ICU admission and days 2-4 were analyzed using a novel POC multiplex micro-ELISA platform and compared with established in-house and commercial ELISAs using Spearman rank correlation and receiver operating characteristic (ROC) analysis. Additional complement activation markers (C3bc, C3bBbP, C1s/C1-INH, MASP-1/C1-INH and C4d) were assessed to explore specific pathway involvement. Results: TCC levels were significantly elevated in patients (median 3575, IQR 2048-6504 mAU/ml) compared with controls (median 1286, IQR 1032-1903 mAU/ml; Conclusion: Point-of-care TCC quantification is feasible, correlates well with established ELISAs and accurately identifies elevated TCC levels in critically ill patients. Although formal method-comparison analyses were not possible to establish, TCC emerged as the most robust marker of complement activation in this ICU cohort using the evaluated POC prototype. POC testing may facilitate timely identification of complement activation in acute care settings and support integration of complement-directed diagnostics and therapeutics into clinical workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.